Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Ashish Bhatia MD, FAAD
Ashish C. Bhatia MD, FAAD Associate Editor
Christen Mowad MD
Christen Maria Mowad MD Advisory Board
Eliot Mostow MD, MPH
Eliot N. Mostow MD, MPH Associate Editor
See All Experts
featured
Published in Dermatology

Journal Scan / Research · January 08, 2022

Nemolizumab Plus Topical Agents Improve Moderate-to-Severe Pruritis in Patients With Atopic Dermatitis

The British Journal of Dermatology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Ashish Bhatia MD, FAAD

Robert Brodell MD, FAAD

Eliot Mostow MD, MPH

The British Journal of Dermatology
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies
Br J Dermatol 2021 Nov 02;[EPub Ahead of Print], K Kabashima, T Matsumura, H Komazaki, M Kawashima

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated